The U.S. Food and Drug Administration (FDA) has granted priority review to Sanofi’s application of Sarclisa (isatuximab) in combination with standard of care for…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Once-weekly induction therapy with bortezomib is as efficient as the standard two times a week dosing in people newly diagnosed with multiple myeloma, a…
Arcellx and Kite Pharma are planning to launch a Phase 3 clinical trial, dubbed iMMagine-3, to test their cell therapy anitocabtagene…
NXC-201, an investigational CAR T-cell therapy, has been designated an orphan drug in the European Union (EU) as a potential treatment of multiple myeloma.
At its 15th annual gala, held in New York City this April, the International Myeloma Foundation (IMF) raised more than $675,000 — monies the…
A unanimous vote by a committee of the U.S. Food and Drug Administration (FDA) could lead to an early outcome measure — one known as…
